Potential mechanisms of photopheresis in hematopoietic stem cell transplantation

被引:78
作者
Peritt, D [1 ]
机构
[1] Therakos Inc, Exton, PA 19341 USA
关键词
photopheresis; graft versus host disease; regulatory T cells; immune tolerance;
D O I
10.1016/j.bbmt.2005.11.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immune tolerance describes specific unresponsiveness to antigens. In clinical situations such as graft-versus-host disease it may be useful to capitalize on these pre-existing tolerance mechanisms to treat patients. Extracorporeal photopheresis is a pheresis treatment whereby the approximately 5x10(9) leukocytes are treated with a photoactivatable compound (8-methoxypsoralen) and UVA light, and immediately returned to the patient in a closed-loop, patient-connected system. This therapy induces apoptosis of virtually all the treated leukocytes. There is growing evidence that infusion of apoptotic cells may trigger certain tolerance mechanisms and, thus, be of therapeutic use in graft-versus-host disease. These apoptotic cells are taken up by phagocytes (antigen-presenting cells) in the body of the patient. Apoptotic cell engagement has been reported to induce several changes and functional activities in the engulfing antigen-presenting cell. These antigen-presenting cells: (1) decrease production of proinflammatory cytokines; (2) increase production of anti-inflammatory cytokines; (3) lower ability to stimulate T-cell responses; (4) delete CD8 T effector cells; and (5) induce regulatory T cells. Any and all of these mechanisms could explain the noted effect in graft-versus-host disease. It is still unclear which one or ones are truly responsible. Ongoing studies in animals and human trials will ultimately unravel these details. (C) 2006 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 55 条
[31]   Induction of tolerogenic DCs: 'you are what you eat' [J].
Mahnke, K ;
Knop, J ;
Enk, AH .
TRENDS IN IMMUNOLOGY, 2003, 24 (12) :646-651
[32]   Immature, but not inactive: the tolerogenic function of immature dendritic cells [J].
Mahnke, K ;
Schmitt, E ;
Bonifaz, L ;
Enk, AH ;
Jonuleit, H .
IMMUNOLOGY AND CELL BIOLOGY, 2002, 80 (05) :477-483
[33]  
Mahnke K, 2003, BLOOD, V101, P4862, DOI 10.1182/blood-2002-10-3229
[34]   The danger model: A renewed sense of self [J].
Matzinger, P .
SCIENCE, 2002, 296 (5566) :301-305
[35]   PHAGOCYTOSIS OF APOPTOTIC NEUTROPHILS DOES NOT INDUCE MACROPHAGE RELEASE OF THROMBOXANE-B2 [J].
MEAGHER, LC ;
SAVILL, JS ;
BAKER, A ;
FULLER, RW ;
HASLETT, C .
JOURNAL OF LEUKOCYTE BIOLOGY, 1992, 52 (03) :269-273
[36]   Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production [J].
Morelli, AE ;
Larregina, AT ;
Shufesky, WJ ;
Zahorchak, AF ;
Logar, AJ ;
Papworth, GD ;
Wang, ZL ;
Watkins, SC ;
Falo, LD ;
Thomson, AW .
BLOOD, 2003, 101 (02) :611-620
[37]   TGF-β regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes [J].
Peng, YF ;
Laouar, Y ;
Li, MO ;
Green, EA ;
Flavell, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (13) :4572-4577
[38]   Type 1 T regulatory cells [J].
Roncarolo, MG ;
Bacchetta, R ;
Bordignon, C ;
Narula, S ;
Levings, MK .
IMMUNOLOGICAL REVIEWS, 2001, 182 :68-79
[39]   Photopheresis: Clinical applications and mechanism of action [J].
Rook, AH ;
Suchin, KR ;
Kao, DMF ;
Yoo, EK ;
Macey, WH ;
DeNardo, BJ ;
Bromely, PG ;
Geng, YM ;
Junkins-Hopkins, JM ;
Lessin, SR .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 1999, 4 (01) :85-90
[40]   Cell-based therapy approaches using dying cells: from tumour immunotherapy to transplantation tolerance induction [J].
Saas, P ;
Tiberghien, P ;
Bittencourt, MD .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (03) :249-263